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Abstract 
The sigma 1 receptor (S1R) is widely expressed in the CNS and is mainly located on the endoplasmic reticulum. 
The S1R is involved in the regulation of many neurotransmission systems and, indirectly, in neurodegenerative 
diseases. The S1R may therefore represent an interesting neuronal biomarker in neurodegenerative diseases 
such as Parkinson’s (PD) or Alzheimer’s diseases (AD). Here we present the characterisation of the 
S1R-specific 18F-labelled tracer 18F-IAM6067 in two animal models and in human brain tissue. 
Methods: Wistar rats were used for PET-CT imaging (60 min dynamic acquisition) and metabolite analysis (1, 
2, 5, 10, 20, 60 min post-injection). To verify in vivo selectivity, haloperidol, BD1047 (S1R ligand), CM398 (S2R 
ligand) and SB206553 (5HT2B/C antagonist) were administrated for pre-saturation studies. Excitotoxic lesions 
induced by intra-striatal injection of AMPA were also imaged by 18F-IAM6067 PET-CT to test the sensitivity of 
the methods in a well-established model of neuronal loss. Tracer brain uptake was also verified by 
autoradiography in rats and in a mouse model of PD (intrastriatal 6-hydroxydopamine (6-OHDA) unilateral 
lesion). Finally, human cortical binding was investigated by autoradiography in three groups of subjects (control 
subjects with Braak ≤2, and AD patients, Braak >2 & ≤4 and Braak >4 stages). 
Results: We demonstrate that despite rapid peripheral metabolism of 18F-IAM6067, radiolabelled metabolites 
were hardly detected in brain samples. Brain uptake of 18F-IAM6067 showed differences in S1R anatomical 
distribution, namely from high to low uptake: pons-raphe, thalamus medio-dorsal, substantia nigra, 
hypothalamus, cerebellum, cortical areas and striatum. Pre-saturation studies showed 79-90% blockade of the 
binding in all areas of the brain indicated above except with the 5HT2B/C antagonist SB206553 and S2R ligand 
CM398 which induced no significant blockade, indicating good specificity of 18F-IAM6067 for S1Rs. No 
difference between ipsi- and contralateral sides of the brain in the mouse model of PD was detected. AMPA 
lesion induced a significant 69% decrease in 18F-IAM6067 uptake in the globus pallidus matching the neuronal 
loss as measured by NeuN, but only a trend to decrease (-16%) in the caudate putamen despite a significant 91% 
decrease in neuronal count. Moreover, no difference in the human cortical binding was shown between AD 









Conclusion: This work shows that 18F-IAM6067 is a specific and selective S1R radiotracer. The absence or 
small changes in S1R detected here in animal models and human tissue warrants further investigations and 
suggests that S1R might not be the anticipated ideal biomarker for neuronal loss in neurodegenerative diseases 
such as AD and PD. 
Key words: Sigma 1 receptor; PET radiotracer; Parkinson’s disease; Alzheimer’s disease; animal model 
Introduction 
Sigma receptors have drawn particular interest 
over the years as potential biomarkers of 
neurodegeneration [1-4]. Pharmacological studies 
have reported the evidence of at least two subtypes, 
i.e. sigma 1 (σ1) and sigma 2 (σ2) receptors [5, 6]. The 
σ1 receptor (S1R) is a highly conserved 25 kD 
molecular chaperone protein with 223 amino acids [6, 
7]. In vitro crystallography revealed that the S1R is 
found in a homotrimeric form with 1 transmembrane 
region per protomer [8], although in vivo studies and 
sequence-based models support 2 transmembrane 
domains, which according to Penke et al. suggest a 
“potentially amorphous intrinsically disordered in 
vivo structure” of S1R [6]. The S1R is expressed mostly 
in the brain, in neurons, oligodendrocytes and 
ependymal cells, but also in peripheral organs and 
tissue (for review see [6]). At a cellular level, S1R is 
mainly located at the endoplasmic reticulum (ER), in 
close contact with mitochondria at the 
mitochondria-associated ER membrane (MAM) [6, 9], 
although S1R can easily translocate to the plasma 
membrane, the nuclear envelope or interact with 
cytosolic proteins with consequences for regulation of 
Ca2+ signalling associated cell survival (for review see 
[6] & [9]). 
The S1R is involved in the regulation of many 
neurotransmission systems such as cholinergic, 
noradrenergic and dopaminergic systems [10], 
although its exact role is still poorly understood. This 
neuro-modulatory role means that S1R is indirectly 
involved in various neuropathology, including 
schizophrenia, depression, stroke, Parkinson’s disease 
(PD) and Alzheimer’s disease (AD) [1, 11, 12]. Some 
studies have shown a link between S1R dysregulation 
and amyotrophic lateral sclerosis, AD or PD 
progression [3, 13-16]. Other studies have 
demonstrated that there is a reduction in the anterior 
putamen S1R density in PD patients [17] and also a 
reduction in cortical and cerebellar S1R density in 
brains of AD patients [18] and in AD post-mortem 
tissues [19, 20]. S1R expression has therefore been 
envisaged as a potential biomarker for neuronal 
function in health and diseases. 
Previously developed S1R PET radiotracers had 
limited and variable affinity and/or selectivity 
towards S1R, with most of them displaying some 
capacity to bind σ2 receptors and/or other 
neuro-receptors (for review see [21, 22]). Amongst the 
S1R radiotracers, 11C-SA4503 (Ki = 4.4 nM, Ki σ2/σ1 = 
55) [23] has been the most used [18, 24, 25] with other 
tracers presenting various levels of selectivity (for 
review see [22]). Amongst all the [18F]-labelled S1R 
radiotracers, 18F-FTC-146 (Ki = 2.5 pM, Ki σ2/σ1 = 
144,800) [26], 18F-fluspidine (Ki = 0.59 nM, Ki σ2/σ1 = 
1330) [27] and 18F-IAM6067 (Ki = 2.6 nM, Ki σ2/σ1 = 
187), presented here, are the most selective for S1R vs 
S2R [22, 28]. Selectivity of 18F-IAM6067 for S1R against 
a broad range of receptors and transporters has been 
previously reported by Moussa et al. (see 
supplementary information in [29] where 18F- 
IAM6067 is compound #30). Although affinity and 
selectivity are essential criterion, in vivo 
pharmacokinetics is an equally important parameter 
as recent studies have shown that 18F-FTC-146 had 
unfavourably slow pharmacokinetic properties for 
human use [30, 31]. Noteworthily, it was shown in 
non-human primate that despite having lower affinity 
(S)-18F-fluspidine (Ki = 2.30 nM) displayed more 
favourable pharmacokinetics for human use than 
(R)-18F-fluspidine (Ki = 0.52 nM) [32]. Hence, taking 
into account all these considerations, to date 
(S)-18F-fluspidine appears to be the most suitable 
candidate for S1R PET imaging in human. 
In this study, we present the validation of the 
S1R specific 18F-labelled tracer 18F-IAM6067 [28] 
(Figure 1). The specificity towards S1R was initially 
evaluated in a Papio hamadryas baboon pre-treated 
with haloperidol (1 mg/kg, i.v.) which resulted in a 
80% displacement in specific receptor binding in all 
areas of the brain [28]. Therefore, the aims of this 
study were to fully evaluate the in vivo brain uptake of 
18F-IAM6067 using in vivo PET imaging; we also tested 
its specificity and selectivity for S1R, S2R and 5HT2B as 
Moussa et al. [29] reported some affinity for those 
receptors (Ki σ2/σ1 = 187, Ki 5HT2B/σ1 = 37). In vivo data 
were confirmed by in vitro autoradiography. 
Furthermore to investigate the potential of S1R as 
neuronal biomarker, we studied 18F-IAM6067 binding 
in vivo and by autoradiography in a model of AMPA 
lesion in Wistar rats, by autoradiography in a mouse 
model of PD, and in AD human tissue as classified by 
Braak staging [33]. 






Figure 1. Chemical structure of N-(2-Benzofuranylmethyl)-N’-[4-(2-fluoroethoxy)benzyl]piperazine (18F-IAM6067). 
 
Materials and Methods 
Radiosynthesis 
N-(2-Benzofuranylmethyl)-N’-[4-(2-fluoroethox)
benzyl]piperazine (IAM6067) was labelled with [18F]. 
The radiosynthesis was previously described by 
Moussa and colleagues [28]. 
Animals 
Forty male Wistar rats (Charles River, Margate, 
UK) were used for in this study. Animals weighed 378 
± 121 g at the time of experimentation and were kept 
under a 12-hour light/dark cycle under steady 
temperature and humidity with access to food and 
water ad libitum. All procedures were carried out in 
accordance with the Animals (Scientific Procedures) 
Act 1986, and the specific project licence was 
approved by the UK Home Office. 
Metabolite analysis in plasma and brain 
Twenty-four rats were anesthetized using 
isoflurane (induction 4-5%, 2-2.5% thereafter in 
70%/30% NO2/O2 mixture at 1 L/min) and 
catheterized (Jelco® I.V. catheter 24G) in the tail vein 
for 18F-IAM6067 administration (32-123 MBq). Blood 
samples were collected at 1, 2, 5 min post-injection 
and at 10, 20, 40 or 60 min post-injection when the 
animals were sacrificed. Seven animals used for 
metabolites analysis were also scanned for 60 min. 
Plasma was isolated by centrifugation (3 min, 3000 × g 
at 4 °C). Two hundred µL of CH3CN was added to 200 
µL of serum for protein precipitation and after 
centrifugation (3 min, 3000 × g at 4 °C), 100 µL of 
supernatant was injected into the HPLC for 
quantification (HPLC equipment: Shimadzu 
prominence with a UV detector and bespoke 
Scintillation detector; column: ACE 3 C18 HL, 
[Hichrom], 150 × 4.6 mm; porosity: 3 μm; solvent A: 
0.1 M ammonium acetate; solvent B: CH3CN, isocratic 
elution: 50:50 (A/B) in 15 min; flow rate: 1 mL/min; 
room temperature; absorbance detection at λ = 254 
nm). Animal brains were removed and then 
homogenised by ultra-Turrax® in 2 mL of ice-cold 
acetonitrile. After centrifugation (3 min, 9000 × g at 4 
°C), the supernatant was separated from the pellet. 
One hundred microliters of brain supernatant were 
injected on the HPLC column (same conditions as 
above). Control samples were spiked with 15 µL of 
stable standard. The parent radiotracer eluted at 11 
minutes. 
AMPA lesion in Wistar rats 
Three rats were anesthetized using isoflurane 
(induction 4-5%, 2-2.5% thereafter in 70%/30% 
NO2/O2 mixture) and stereotaxically injected with 7.5 
nmol of α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA, 7.5 mM in PBS buffer, Tocris 
Bioscience, UK) through the use of a 2 µL 
microsyringe (Hamilton Neuros syringe Model 
7002KH point style 3) and micropump (injection rate: 
0.5 µL/min, UltraMicroPump II and Micro4 
Controller, WPI Inc., USA) in the right striatum 
(Bregma +0.7 mm, from sagittal suture: 3 mm, depth 
from brain surface: 5.5 mm). Animals were 
maintained normothermic (body temperature: 37.0 ± 
0.4 °C) during the surgery through the use of a 
heating blanket (Homeothermic Blanket Control Unit, 
Harvard Apparatus Limited®, Edenbridge, Kent, 
UK). Twenty-four hours later, the rats were 
anesthetized again as described above and scanned 
with a 3T cryogen-free MRS 3000 scanner with a 
quadrature, rat head coil (MR Solutions, Guildford, 
UK) [34, 35] to assess oedema (i.e. lesion size and 
location) immediately before the PET scan. 
Parameters for the T2-weighted RARE sequence were: 
repetition time = 4800 ms, base echo time = 17 ms, 
effective echo time = 68 ms, number of echoes = 8, 
bandwidth = 20 kHz, number of samples = 256, 
number of views = 240, number of averages = 1 with 
25 slices of 1.06 mm, giving a final voxel size of 0.136 × 
0.136 × 1.06 mm. 
Animal PET and data acquisition 
Sixty minutes PET scans were performed on 23 
animals on a Siemens Inveon® PET/CT scanner 
(Injected dose: 38±11MBq). Eight of them were used 
for basal uptake. To assess the in vivo specificity of 
18F-IAM6067, 2 of those eight rats were also used for 
the pre-saturation protocol (BD1047) on a different 
day. Nine rats were scanned for pre-saturation studies 
with haloperidol (n = 3 scans) and/or BD1047 (n=4 
scans) and/or SB206553 (n = 5 scans) on different 
days. An additional three rats were scanned with 





18F-IAM6067 alone and 3 days later with 18F-IAM6067 
after pre-treatment with the S2R antagonist CM398 
[36]. These pre-saturation studies were conducted by 
injecting 1mg/kg of haloperidol (D2/σ receptor 
antagonist; Tocris Bioscience, UK; n = 3) [37, 38], 
BD1047 (S1R antagonist; Tocris Bioscience, UK; n = 4) 
[39], SB206553 (5-HT2B/5-HT2C receptor antagonist; 
Tocris Bioscience, UK; n = 5) or CM398 (S2R 
antagonist, kindly provided by Dr McCurdy; n = 3) 
i.v. 20-30 min before scan start. Animals scanned on 
multiple occasions (with/without blocking or 
different blocking agent) were always scanned at least 
24 h apart. Three additional rats received intra-striatal 
AMPA and were scanned with 18F-IAM6067 24 h after 
lesion. Each rat was anesthetized using isoflurane 
(induction 4-5%, 2-2.5%) and catheterized in the tail 
vein for blocking agent and 18F-IAM6067 injection. 
Animal respiration and temperature were controlled 
using a pressure-sensitive pad and rectal probe 
(BioVet, m2m Imaging Corp., Cleveland, OH, USA) 
and body temperature was maintained at 37 ± 0.7 °C 
via the interface managed by the BioVet system. 
PET-CT was performed as previously described [40]. 
Briefly, a CT scan was performed prior to the PET 
acquisition for attenuation correction. The list mode 
emission data were histogrammed into 3D sinograms 
of 35 dynamic frames, normalized, corrected for 
dead-time, attenuation, scatter and radioactive decay, 
and reconstructed using OSEM3D (16 subsets and 4 
iterations) into images of dimensions 128 × 128 × 159 
voxels of volume 0.776 × 0.776 × 0.796 mm3. 
PET image analysis 
PET-CT images were co-registered with the rat 
MRI template and its associated intracranial mask as 
published by Schwarz et al. [41] and generously 
provided by GSK. To co-register the MRI template 
and PET-CT images, individual brain masks were 
delineated on each CT image and co-registered with 
the MRI brain mask using rigid registration with 
mutual information. Image analysis and 
quantification was performed using the BrainVisa/ 
Anatomist software (http://www.brainvisa.info) 
using the geometric transfer matrix (GTM) and 
ROIopt methods for partial volume correction both 
described and used previously [42-46]. Modified 
larger ROIs were drawn on the MRI anatomical 
template [41] for 18F-IAM6067 quantification. PET 
data were expressed as SUV. 
Parkinson’s disease mouse model 
C57Bl6 mice were bred in the animal facility of 
the European Institute for Molecular Imaging 
(University of Muenster). Animal experiments were 
performed in accordance with the German laws for 
animal protection and were approved by the local 
bureau for animal care (LANUV, Landesamt für 
Natur, Umwelt und Verbraucherschutz Nordrhein- 
Westfalen). For stereotactic injections, mice (n = 6) 
were anaesthetised (ketamine/xylazine i.p.) and 
placed into a stereotactic frame. A small skin incision 
followed by craniotomy was performed. The needle 
was placed in position (coordinates: AP: +0.5 mm; 
ML: -2.0 mm; DV: -3.0 mm) and after 1 min, 2 µL of 5 
mg/mL 6-hydroxydopamine (6-OHDA) in 0.9% NaCl 
and 0.02% ascorbic acid were injected into the left 
striatum using a 5 µL Hamilton 7005KH syringe. The 
syringe was kept in place for 5 min in order to allow 
the solution to diffuse into the surrounding tissue and 
was then retracted slowly. 
Human tissue 
Post-mortem brain tissues of 23 cases (8 men and 
15 women) were obtained from the Manchester Brain 
Bank through appropriate consenting procedures for 
collection and use of the human brain tissues. 
Pathological diagnoses were made by an experienced 
neuropathologist (DM) as previously described [47, 
48] and were in accordance with recent National 
Institute on Ageing - Alzheimer's Association 
guidelines for the neuropathological assessment of 
AD [49]. By such classification, only cases with Braak 
stages 5 and 6 were classed as definite AD. Cases with 
Braak Stages >2 & ≤4 were not diagnosed as definite 
AD, but these could be considered as cases of possible 
(incipient) AD, thereby representing cases with early 
changes of AD. Amyloid plaque load per se was not 
employed for classification of AD, although it is 
acknowledged that neuritic plaque scores do form the 
basis of CERAD classification. Clearly, in terms of 
amyloid plaques alone, there was overlap in amyloid 
load between cases at Braak stage >2 & ≤4 and those at 
Braak stages 5 and 6. Subjects were therefore split in 
three groups based on their Braak stages [33]: controls 
(Braak ≤2, 8 subjects), subclinical AD (Braak >2 & ≤4, 8 
subjects) and AD (Braak >4, 7 subjects). Details of each 
case are described in Table 1. Hence, brains in the first 
group were considered as a (normal) control group 
(Braak ≤2). These were obtained from aged patients 
with no history of neurological disease and no 
pathological evidence of AD or other degenerative 
brain disease. The second group (Braak >2 & ≤4) 
consisted of patients with mild to moderate AD-type 
pathology, whilst the last group (Braak >4) all showed 
abundant plaques and tangles throughout all cortical 
regions and met pathological criteria for established 
AD [49, 50]. The average post-mortem delay was also 
similar for all groups (mean ± SD [min.-max.]: 34.9 ± 
11.3 [12-46]; 35.8 ± 9.9 [25-48] and 41.5 ± 14.2 [24-64] 
hours for controls, subclinical AD and AD groups, 





respectively). Subsequently to the autoradiography 
experiments, measurements from frontal cortex of 
case #3 were not included as the sections had been 
damaged during the experiments (Table 1). 
Immunohistochemistry 
Two weeks after 6-OHDA lesion, animals were 
sacrificed by cervical dislocation and brains were 
removed and frozen in -40°C isopentane. 
Cryosections of 20 µm thickness were cut every 
500µm, resulting in 16 levels per brain. In order to 
assess the effect of the 6-OHDA on the striatal 
dopaminergic neurons of the C57Bl6 mice, 
immunohistochemistry for tyrosine-hydroxylase was 
performed using the following protocol: brains were 
post-fixed with 4% PFA in PBS for 15 min at 4 °C, then 
washed with PBS (3 × 5min). For antigen retrieval, 
sections were boiled for 25 min in citrate buffer (pH 
6), left in the buffer to cool down for 20 min, and 
washed with PBS (3 × 5 min). Blocking was performed 
with Peroxidase-blocking solution (S2023, Dako, 
Hamburg, Germany) for 10 min followed by a PBS 
washing step (3 × 5 min). After incubation with 
primary antibody (chicken anti-tyrosine-hydroxylase, 
Abcam ab76442, 1:800, Abcam, Cambridge, UK) over 
night at 4 °C in antibody diluent (S3022, Dako), 
sections were washed (PBS, 3 × 5 min), incubated with 
biotinylated secondary antibody (DSB-XTM Biotin 
Goat Anti-Chicken IgG 1:800, Life Technologies, 
Carlsbad, CA, USA) in antibody diluent for 60min, 
washed (PBS, 3 × 5 min) and incubated with HRP 
Streptavidin conjugate (1:600 in PBS, P0397, Dako) for 
45min. After washing (PBS, 3x5min), sections were 
placed in 2% 3,3'-Diaminobenzidine (DAB), 0.0012% 
H2O2 until reaching a good staining intensity. Sections 
were dehydrated in 70 %, 80 %, 96% ethanol, 100% 
isopropanol and xylene (each twice) and mounted in 
Entellan (Merck Millipore, Burlington, MA, USA). 
Images were collected on a Nikon ECLIPSE Ni-E 
upright microscope using a 10×/0.30 or 20×/0.50 
UPlanFLN objectives operated by the NIS Elements 
AR software (Nikon Instruments Inc., Tokio, Japan). 
Immunohistochemistry was also carried out in 
rats that received intrastriatal AMPA to visualise 
NeuN (neuronal marker). Animals were culled by 
isoflurane overdose confirmed by cervical dislocation. 
The brains were collected, snap frozen using 
isopentane on dry ice and stored at -80 °C. Coronal 
brain sections (20 µm thick) were taken using a 
cryostat (Leica CM3050s, Leica Biosystems Nussloch 
GmbH, Germany) and stored at -80 °C. Sections were 
allowed to defrost and dry at room temperature for 
20min and then fixed with 4% paraformaldehyde for 
10 min before being washed (6 × 5 min) in phosphate 
buffered saline (PBS) and incubated for 30 min in 2% 
normal donkey serum and 0.1% Triton X-100 in PBS to 
permeabilise and block non-specific binding. Primary 
antibody incubation was carried out overnight at 4 °C 
with rabbit anti-NeuN (Abcam, ab177487, 1:500). 
Following incubation in primary antibody, PBS 
washes were repeated (3 × 10min) and incubation 
with the secondary antibody (Alexa Fluor 594nm 
Donkey anti-rabbit IgG 1:500) was carried out. Images 
of the lesioned striatum were collected on an 
Olympus BX51 upright microscope using a 10×/0.30 
UPlanFLN objectives and captured using a Retiga 
6000 Color and R6 camera through QCapture Pro 7 
and Ocular Software (QImaging Inc.). Specific band 
pass filter sets were used to prevent bleed through 
from one channel to the next. NeuN staining was 
quantified using ImageJ (1.52n) [51-53] using 5 
snapshots for the caudate putamen, 3 snapshots for 
the globus pallidus and 2 snapshots for the substantia 
nigra for each side of the brain (ipsi- and 
contralateral). Both the total number of neurons 
averaged over the snapshots and the percentage of 
stained areas were measured. 
Autoradiography 
18F-IAM6067 autoradiography was performed 
using 20µm fresh frozen brain sections from 6 naïve 
and 3 AMPA-injected Wistar rats, 6 C57Bl6 mice and 
also from the 23 human cases. Sections of frontal 
(Brodmann areas 8/9) and temporal cortex 
(Brodmann areas 21/22) were cut from frozen human 
tissue blocks. Human and rodents sections were 
mounted on to glass slides (SuperFrost Plus Gold and 
SuperFrost Plus slides, Thermo Fisher Scientific Inc., 
MA, USA for human and animal tissues, 
respectively). For all steps described below, Tris 
buffer (Trizma pre-set crystals (Sigma, UK), 50 mM, 
with 120 mM NaCl, with pH adjusted to 7.4 at 4 °C or 
room temperature) was used. Slides were allowed to 
defrost then pre-incubated in Tris Buffer at 4 °C for 
5min. Slides were then incubated with 18F-IAM6067 (2 
nM) in Tris Buffer at room temperature for 60 min to 
determine total binding. Adjacent sections were 
incubated with the same solution containing an excess 
of unlabelled IAM6067 (2 µM) to assess non-specific 
binding. Next the slides were washed 2 × 2 min in Tris 
buffer at 4 °C, followed by a quick rinsing in distilled 
water at 4 °C. Slides were then dried promptly before 
exposition on Phosphor-Imager plates overnight. 
Autoradiographs were analysed using AIDA software 
(Raytest GmbH, Germany). Regions of interest (ROI) 
were manually drawn (amygdala, striatum, cingulate 
cortex, sensorimotor cortex (SS), hippocampus, 
hypothalamus, pons, thalamus medio-dorsal (MD), 
region containing the ventral tegmental area and the 
substantia nigra (VTA/SN) and the cerebellum for the 





naive rat tissue; the ipsi- and contralateral striatum 
(the ipsilateral striatum includes the lesioned part of 
both the caudate-putamen and globus pallidus pooled 
together notably because accurate anatomical 
delineation of both brain regions on the 
autoradiography was difficult) and cortex for the 
AMPA-injected rats; the ipsi- and contralateral parts 
of the cingulate cortex, striatum, CM thalamus and 
VTA/SN for the mouse tissue; the grey and white 
matter for the human tissue). Specific binding (total 
binding minus non-specific binding) in each ROI is 
expressed as intensity of the photostimulated 
luminescence (PSL) per pixel. 
Statistical analysis 
All data are expressed as mean ± standard 
deviation (SD). Statistical significance was accepted at 
P<0.05 level. Statistical tests were performed using 
GraphPad Prism 8.4 for Windows (GraphPad 
Software, CA, USA, www.graphpad.com) and P 
values adjusted for multiple comparisons are reported 
for Sidak’s post-hoc tests. 
PET data 
For uptake of 18F-IAM6067 without and with 
blocking compounds, values were analysed using 2 
way ANOVA (ROI as repeated factor and treatment; 
i.e. baseline vs blocking), the scans with haloperidol, 
BD1047 or SB206553 pre-treatment were compared to 
baseline scans. As the experiments with CM398 were 
performed later, scans without and with 
pre-treatment with CM398 were performed in the 
same animals and therefore were analysed using 2 
way ANOVA with repeated measures for ROI and 
treatment. ANOVA were followed by a Sidak’s 
post-hoc test. For comparisons between baseline vs 
haloperidol, BD1047 and SB206553 pre-treatments 
and baseline vs CM398, and between ROIs, 
considering the large number of comparisons, the 
more conservative option of one family for all 
comparisons was applied for the Sidak’s post-hoc test. 
For the AMPA experiment, comparison of 
18F-IAM6067 uptakes by PET in ipsi- vs contralateral 
vs lesion in the caudate-putamen and globus pallidus 
(as delineated on the T2 MRI) ROIs and comparisons 
all ROIs of control (no lesion) vs AMPA-injected 
animals were performed using a 2 way ANOVA 
followed by a Sidak’s post-hoc test. 
Autoradiography data 
Specific binding in the ipsi- and contralateral 
striatum in the rat AMPA model was analysed with a 
paired t-test. 
Specific binding between the ipsi- and 
contralateral parts of each region in the PD mouse 
model 18F-IAM6067 autoradiography was analysed 
using a 2 way ANOVA (both ROI and side, ipsi- vs 
contralateral, as repeated factors). The 2 way ANOVA 
only returned an effect of ROI (p=0.003) but no 
significant differences between ipsi- and contralateral 
side or interaction (p=0.84 and p=065 respectively), 
therefore a Sidak’s post-hoc test comparing ROIs only 
was performed. 
 
Table 1. Clinical summary of autopsy cases used for the 18F-IAM6067 autoradiography experiments 
Case no. Gender Age of death (years) PM delay (hours)  Principal pathological diagnosis Age of disease onset (years) Braak stage 
1 M 54 37 Normal brain N/A ≤2 
2 M 95 12 Age changes only N/A ≤2 
3* F 72 41 Age changes only N/A ≤2 
4 F 81 41 Age changes only N/A ≤2 
5 F 82 46 Age changes only N/A ≤2 
6 F 89 41.5 Age changes only N/A ≤2 
7 F 87 24 Age changes only N/A ≤2 
8 F 92 37 Age changes only N/A ≤2 
       
9 M 82 40 Moderate AD 75 >2 & ≤4 
10 F 93 41 Mild AD N/A >2 & ≤4 
11 M 89 48 Mild AD N/A >2 & ≤4 
12 F 92 25 Severe CAA 84 >2 & ≤4 
13 M 91 33 Moderate AD 84 >2 & ≤4 
14 M 86 26 AD N/A >2 & ≤4 
15 F 97 25 AD N/A >2 & ≤4 
16 F 84 48 AD 78 >2 & ≤4 
       
17 M 62 50 AD 56 >4 
18 M 73 36 AD 60 >4 
19 F 85 24 AD N/A >4 
20 F 91 45 AD N/A >4 
21 F 82 46 AD 68 >4 
22 F 71 64 AD 64 >4 
24 F 81 25.5 AD 74 >4 
PM: post-mortem delay; CAA: cerebral amyloid angiopathy; AD: Alzheimer’s disease; N/A: not available/applicable. * Measurements from frontal cortex of case #3 were not 
included as the sections had been damaged during the experiments.





Specific binding for human autoradiography 
across the three groups in both frontal and temporal 
cortex and for grey and white matter was analysed by 
mixed-model fitting (brain structures as repeated 
factor). As this analysis only returned an effect for the 
brain structures factor and not for the Braak stage, a 
Sidak’s post-hoc test comparing brain regions only 
was performed. 
Immunohistochemistry data 
For NeuN staining analysis and 18F-IAM6067 
autoradiography in the AMPA model, percentage 
stained area, cell counts and 18F-IAM6067 were 
analysed using paired t-tests (ipsi- vs contralateral) for 




On average, about 2.96 GBq (range 0.53-11.3 
GBq) of 18F-IAM6067 (>98.5% radiochemically pure) 
were routinely obtained within 65 min of 
radiosynthesis (including high-performance liquid 
chromatography (HPLC) purification and 
formulation), with molar activities ranging from 55 to 
345 GBq/µmol. 
Metabolites analysis 
Metabolites analysis revealed 3 fractions of the 
radiotracer with retention times at 1.4 and 1.8 min for 
metabolites and between 10.9 and 11.1 min for the 
parent fraction (in the plasma and the brain, 
respectively) (Table 2). Moreover, radiolabelled 
metabolites analysis showed rapid metabolism of 
18F-IAM6067 (only 10.1 ± 8.6% of intact tracer in 
plasma at 10 min post-injection) (Table 2). On 
contrary, more than 91% of the intact 18F-IAM6067 
was found in the brain at 10, 20 and 60 min 
post-injection. Metabolites represented only a minor 
fraction of radioactivity found in the brain 
(undetectable at 1, 2 and 5 min post-injection and less 
than 10% at 10, 20 and 60 min post-injection) (Table 2). 
The retention times of these 2 metabolites (1.4 and 
1.8min, Table 2) suggest that they were more 
hydrophilic than the parent compound. 
Tracer brain uptake and distribution 
The average brain uptake of the radiotracer 
between 20 and 60 min post-injection in several brain 
regions is shown in Figures 2 & 3. Pharmacokinetic 
time-activity curves at baseline and after pre- 
saturation with BD1047 in the rat thalamus medio- 
dorsal and amygdala highlighted the specificity of 
18F-IAM6067 bindings for the S1R (i.e. full blocking by 
BD1047, Figure 3A, C & E). 18F-IAM6067 brain uptake 
was rapid and attained a maximum level (3.3 and 5.5 
SUV in amygdala and thalamus medio-dorsal 
respectively) at 2.25 min post-injection and then 
progressively and slowly washed out up to 60min. At 
baseline, the lowest average uptake of 18F-IAM6067 
was detected in the caudate/putamen (2.3 ± 0.1 SUV), 
in the cingulate cortex (2.3 ± 0.2 SUV) and the 
temporal cortex (2.5 ± 0.2 SUV) (Figure 2A). The 
highest uptakes were found in the substantia nigra (3.8 
± 0.7), thalamus medio-dorsal (3.9 ± 0.4 SUV), 
mesencephalic region (4.7 ± 0.3 SUV) and pons-raphe 
(6.4 ± 0.8 SUV) (Figure 2A). Comparisons of 
18F-IAM6067 uptake between all ROIs are shown 
Figure 2B. Those results were confirmed by 
18F-IAM6067 autoradiography in rat brain regions 
which showed similar anatomical distribution of 
18F-IAM6067 binding as the PET imaging (Figure 4). 
The highest specific binding was observed in the pons 
(7.24 ± 0.89 PSL/pixel) and the hypothalamus (6.79 ± 
0.95 PSL/pixel) and the lowest specific binding in the 
striatum (4.56 ± 0.42 PSL/pixel) and the cingulate 
(4.96 ± 0.26 PSL/pixel) and somatosensory cortices 
(4.49 ± 0.51 PSL/pixel) (Figure 4). 
Pre-saturation with SB206553 (5HT2B/C 
antagonist, blue bars, Figure 3C & E) or CM398 (S2R, 
Figure 3B, D & E) did not reveal any significant 
difference with baseline uptake. Pre-saturation 
studies with haloperidol (D2/σ receptor antagonist; 
orange bars) or BD1047 (S1R antagonist; red bars) 
showed a significant decrease (between 79-90%) of 
18F-IAM6067 uptake in all areas of the brain (Figure 
3B, C & E) which abolished all differences between 
ROIs.
 
Table 2. Percentage of 18F-IAM6067 (parent fraction and metabolites) in rat brain and plasma at 1, 2, 5, 10, 20 and 60 min post-injection. 
Rt indicates the retention time of each fraction of the radiotracer. Data expressed as mean ± SD 
 Metabolites Rt Time (min)  
1 2 5 10 20 60 
Br
ai






M2 1.8 ND ND ND 3.9±2.0 2.6±0.8 1.5±0.7 




a M1 1.4 8.9±8.1 41.5±4.4 77.6±11.6 84.4±17.3 87.3±19.1 99.7±0.8 
M2 1.8 7.0±0.0 0.0 0.0 24.4±5.8 24.1±20.0 2.1±0.0 
Parent 10.9 88.8±12.1 58.3±4.1 22.4±11.6 10.1±8.6 9.8±4.2 0.0 
M1: metabolite 1; M2: metabolite 2; ND: not determined. Rt = retention time (min). 






Figure 2. (A) Average uptake (from sum-image 20-60min post-injection) of 18F-IAM6067 in different brain regions in rats (n=8, data are expressed as SUV mean ± SD). (B) Heat 
map of the adjusted P values (Sidak’s post-hoc test) showing all the comparisons between the various brain regions for 18F-IAM6067 uptake. Non-significant differences are shown 
in blue. (C) PET sum-image (20-60min) co-registered with CT showing 18F-IAM6067 uptake with hippocampus, thalamus medio-dorsal, frontoparietal somatosensory cortex and 
amygdala highlighted by dotted lines. 






Figure 3. Pharmacokinetic time-activity curves in rat thalamus medio-dorsal and amygdala showing 18F-IAM6067 uptake at baseline (n=8) and after pre-saturation with S1R 
antagonist BD1047 (n=4) (A) or at baseline (n=3) and after pre-saturation with S2R antagonist CM398 (n=5) (B). (C) Comparison of average uptake (from sum-image 20-60min 
post-injection) of 18F-IAM6067 between baseline (no pre-treatment, n=8, green bars) and SB206553 (n=5, blue bars), haloperidol (n=3, orange bars) or BD1047 (n=4, red bars) 
pre-saturations and (D) between baseline and CM398 pre-treatment (n=3) in different brain regions (Data are expressed SUV mean ± SD). (E) Co-registered PET-CT images 
showing 18F-IAM6067 uptake at baseline and with pre-saturation with haloperidol, SB206553, BD1047 or CM398 (sum-image 20-60min after injection of the radiotracer); outline 
of the frontoparietal somatosensory cortex (dark red), hippocampus (yellow), thalamus medio-dorsal (purple) and amygdala (orange) regions of interest are shown. 






Figure 4. (A) quantification of 18F-IAM6067 specific binding as measured in rats by in vitro autoradiography in various brain regions. Data expressed as mean ± SD (n=6) of 
photostimulated luminescence (PSL) unit per pixel. VTA/SN: ventral tegmental area/substantia nigra. (B) Representative autoradiograms showing total and non-specific binding in 
different rat brain regions. 
 
Excitotoxic lesion model in rats 
AMPA injection in the striatum resulted in a 
significant neuronal loss 24h post-injection 
characterised by oedema visible on the T2 MRI 
(Figure 5A) and as quantified by NeuN staining 
(Figure 6). 18F-IAM6067 PET imaging revealed only a 
non-significant trend to decrease in 18F-IAM6067 
uptake in the caudate-putamen (-16 ± 11%, Figure 5B) 
despite a significant loss of neurons (-81 ± 3% in % 
stained area and -71 ± 3% in cell number, Figure 6A), 
18F-IAM6067 uptake was however significantly 
reduced in the globus pallidus (-69 ± 5%, Figure 5B) 
matching the significant loss of neurons detected by 
NeuN immunohistochemistry in this ROI (-71 ± 8% in 
% stained area and -56 ± 17% in cell number, Figure 
6B). Comparing all the ROIs in control animals (no 
lesion) with AMPA-lesioned rats revealed a 
significant increase in 18F-IAM6067 uptake in both 
ipsi- and contralateral Substantia nigra and pons-raphe 
(Supplementary Figure 1A and B) although no 
changes in NeuN immunostaining could be detected 
in those brain regions (Supplementary Figure 1C); 
18F-IAM6067 uptake was not affected in any other 
brain areas (Supplementary Figure 1A and B). 
The post-mortem autoradiographic analysis of 
the 18F-IAM6067 binding in the ipsi- vs contralateral 
striatum (caudate-putamen + globus pallidus) of the 
same animals revealed a significant decrease (-38 ± 
8%, Figure 5C & D). 
6-OHDA Parkinson’s disease model in mice 
In the PD mouse model, the 2 way ANOVA 
returned an effect of ROI (p=0.003) only. No 
differences between ipsilateral and contralateral sides 
or interaction ROI × side were identified (p=0.84 and 
p=0.65 respectively) (ipsi- vs contralateral; cingulate 
cortex: 4.21 ± 0.87 vs 4.29 ± 0.84 PSL/pixel, striatum: 
3.39 ± 0.49 vs 3.30 ± 0.55 PSL/pixel, thalamus 
medio-dorsal: 3.25 ± 0.64 vs 3.22 ± 0.65 PSL/pixel and 
ventral tegmental area/substantia nigra: 3.82 ± 1.25 vs 
3.92 ± 1.08 PSL/pixel) despite evidence of a clear 
lesion of the dopaminergic neurons as detected by 
tyrosine hydroxylase immunohistochemistry (Figure 
7). 
Autoradiographic study of brains from 
Alzheimer’s disease patients 
The specific binding of 18F-IAM6067 was also 
investigated by autoradiography in the grey matter of 
controls (Braak stage ≤2), subclinical AD (Braak stage 
>2 & ≤4) and AD (Braak stage >4) subjects in the 
frontal and in the temporal cortex. Only a significant 
difference between grey and white matter could be 
detected, white matter being significantly lower than 
grey matter (Figure 8). No differences between Braak 
stage or interaction brain structures × Braak stage 
were detected (p=0.095 and p=0.91, respectively) (2.37 
± 1.09 vs 3.11 ± 0.84 vs 3.27 ± 0.90 PSL/pixel, for 
controls, subclinical AD and AD groups, respectively, 
in the frontal grey matter and 2.56 ± 1.24 vs 2.98 ± 1.15 
vs 2.91 ± 1.20 PSL/pixel, for controls, subclinical AD 
and AD groups, respectively, in the temporal grey 
matter) (Figure 8). 
Discussion 
Brain uptake, distribution and selectivity of 
18F-IAM6067 
Here we investigated the S1R PET tracer 
18F-IAM6067 and demonstrated that brain distribution 
was in good agreement with the known distribution 





of S1R in the rat brain [54-56]. Despite rapid 
metabolism in plasma, 18F-IAM6067 brain uptake was 
fast and allowed for accurate and specific 
quantification of S1R by PET imaging. Using two 
different animal models of neurodegeneration and 
human brain samples, our results suggest that the 
expression levels of S1R might not be directly related 




Figure 5. (A) representative 18F-IAM6067 PET-MR fused image and T2-MR image (insert, with the lesion in the globus pallidus as delineated on the T2 image in pink) 24h after 
intra-striatal injection of AMPA (7.5 nmol). (B) Quantification of the 18F-IAM6067 uptake in the ipsilateral (healthy), contralateral and lesioned Caudate-Putamen and Globus 
pallidus. (C) Representative autoradiograms of the same rat brain than in (A) showing the total and non-specific binding of 18F-IAM6067. The location of the lesion (minus piece 
of missing tissue indicated by the dashed pattern) is delineated by red dotted line and arrows while the contralateral side is delineated by green dotted line and arrows. (D) 
Quantification of the specific binding as quantified by autoradiography in the cortex and contralateral and ipsilateral caudate-putamen+globus pallidus. Data are expressed as mean 
± SD (n=3). PET data were analysed with a 2 way ANOVA (brain structures & side, ipsi- vs contralateral) followed by a Sidak’s post-hoc test. Contra- and ipsilateral sides for the 
autoradiography were compared with a paired t-test. * And *** indicates p<0.05 and p<0.001 respectively. 






Figure 6. Quantification of the neuronal density (as percentage of stained area and cells/mm²) (left panel) and representative images of the NeuN immunostaining in the ipsi- and 
contralateral side of the caudate-putamen (A) and globus pallidus (B) 24h after intrastriatal AMPA injection in rats. Data are shown as mean ± SD. Data were analysed using paired 
t-tests. * And ** indicate p<0.05 and p<0.01 respectively. 






Figure 7. (A) Quantification by autoradiography of the 18F-IAM6067 specific binding in various contralateral and ipsilateral brain regions of the 6-OHDA Parkinson’s disease 
mouse model. Data are expressed as mean ± SD (n=7). (B) Representative autoradiograms of a mouse brain showing the total and non-specific binding of 18F-IAM6067. (C) 
Representative immunohistological staining against tyrosine hydroxylase (Tyr-OH IHC) showing the significant loss of dopaminergic neurons in the ipsilateral striatum. The 
location of the lesion is delineated by red dotted line and arrows while the contralateral side is delineated by green dotted line and arrows on both the autoradiograms and 
immunostaining. NS: non-specific; CG: cingulate cortex; MD: medio-dorsal; VTA/SN: ventral tegmental area/substantia nigra. Data were analysed using a 2 way ANOVA (brain 
structures & side, ipsi- vs contralateral), there was no significant differences between ipsi- and contralateral side and no significant interaction between ROI and side. 
 
Figure 8. Quantification by autoradiography of the 18F-IAM6067 specific binding in the grey (top panel) and white matter (bottom panel) of control subjects (Braak ≤2, n=7-8), 
subclinical AD (Braak >2 & ≤4, n=8) and AD patients (Braak >4, n=7) in frontal cortex (left panel) and in temporal cortex (right panel). Data are expressed as mean ± SD. Data 
were analysed by mixed-model fitting (brain structures as repeated factor). As this analysis only returned an effect for the brain structures factor (p<0.001) and not for the Braak 
stage (p=0.095) or interaction brain structure × Braak stage (p=0.91), a Sidak’s post-hoc test comparing brain regions only was performed, for both brain structure and all Braak 
stage, specific binding in white matter was significantly lower than in grey matter. 





The S1R-system regulates most of the major 
neurotransmission systems such as cholinergic, 
noradrenergic and dopaminergic systems [10] in the 
CNS and as such S1R has emerged as a potential 
biomarker of neuronal function. For example, Mishina 
et al. have reported a decrease in S1R density in PD 
patients [17] in the anterior putamen and reduction in 
cortical and cerebellar S1R density in brains of AD 
patients [18] and others have reported decreases in 
S1R density in post-mortem tissue of AD patients [19, 
20]. Therefore, the evaluation of suitable (i.e. high 
selectivity notably vs S2R and other targets) S1R 
radiotracers is still required to investigate S1R density 
non-invasively in vivo, notably because many S1R 
tracers developed in the past displayed low affinity 
for S1R, unfavourable brain penetration [57] and/or 
insufficient σ1/σ2 selectivity. 18F-FTC-146 [26] and 
18F-fluspidine [27] are however the two noteworthy 
exceptions of previously reported 18F-labelled S1R 
tracers with high S1R affinity and σ1/σ2 selectivity. 
18F-FTC-146 has been used in a preclinical model [58] 
and in a clinical case of peripheral injury [59] although 
it was also found to have slow brain pharmacokinetic 
for its use in human [30, 31]. Conversely, (S)-18F- 
fluspidine seems to have suitable pharmacokinetics 
and metabolism in human [60, 61] and is now being 
used in clinical studies [62, 63]. 18F-IAM6067 had 
already been shown to have sufficient selectivity 
against S2R (Ki σ2/σ1 = 187) and other targets (see 
supplementary data in [29] in which 18F-IAM6067 is 
compound #30 page S3). We present here the 
evaluation of 18F-IAM6067 as a S1R specific PET tracer 
and confirmed its σ1/σ2 suitable selectivity in vivo 
(Figure 3D). Metabolite analysis revealed a rapid 
metabolism of the parent fraction of 18F-IAM6067 in 
rat plasma (approximatively 10% at 10 and 20 min, 
and not detectable at 60 min post-injection) (Table 2). 
Conversely, in brain most of the radioactivity detected 
was due to the parent compound (≥91% of the intact 
tracer at 10, 20 and 60 min post-injection) and only a 
small amount of metabolites detected in plasma could 
be detected in brain. While we cannot totally exclude 
that the metabolites were able to cross the blood-brain 
barrier (BBB), the small amount detected (8.0 ± 6.2% of 
the total activity 60 min post-injection) as well as the 
low HPLC retention time (1.4 and 1.8min), suggesting 
a high hydrophilicity, support the hypothesis that the 
metabolites detected in brain are from blood left in the 
samples rather than from crossing the blood brain 
barrier. This would therefore support the notion that 
the 18F-IAM6067 brain signal detected in our 
experiments was most likely caused by intact 
radiotracer in the brain. Pre-saturation studies with 
haloperidol (non-selective Dopamine D2/σ1 receptors 
antagonist) or BD1047 (S1R specific antagonist) 
resulted in 79-90% blocking of 18F-IAM6067 uptake 
(see Figure 3A, C & E) and abolished all ROI 
differences, hence indicating presence of specific 
binding in all brain areas. To further verify the 
selectivity of 18F-IAM6067 vs S2R, we performed 
repeated scans with and without pre-saturation with 
the highly selective S2R ligand CM398 (Ki σ1/σ2 = 331) 
[36]. Injection of cold CM398 did not result in a 
significant reduction of 18F-IAM6067 uptake (Figure 
3B, D & E). We also assessed specificity towards 
5HT2B/C receptors as Moussa et al. [29] reported a Ki 
ratio (5HT2B/S1R) of only 37, when compared with 
the σ2/σ1 ratio of 187. Our pre-saturation experiment 
using 5HT2B/C antagonist SB206553 showed no 
significant difference in brain uptake in any of the 
brain ROIs studied (Figure 3C & E), hence supporting 
the selectivity of 18F-IAM6067 towards S1R vs 5HT2B/C 
receptors. Overall, the results of the pre-saturation 
studies and the presence of specific binding 
throughout the brain are in agreement with the 
previous reports [10, 28]. However, the presence of 
specific binding in all ROIs prevents the use of any 
brain region as a reference tissue for modelling 
purpose. From an anatomical point of view, our 
autoradiography study in rats was in good agreement 
with our in vivo PET study. Overall, these results 
validate the fact that 18F-IAM6067 is a suitable specific 
and selective S1R radiotracer, although the slow 
pharmacokinetic of 18F-IAM6067 in primate [28] may 
limit its usefulness in clinical studies. 
Evaluation of 18F-IAM6067 and S1R as 
biomarker of neuronal loss 
The second objective of this study was to assess 
S1R as a biomarker of neuronal function in focal 
neurodegenerative disease models. First, we used an 
acute model of neurodegeneration induced by AMPA 
excitotoxicity in the striatum. As previously reported 
by us and others [64-66], intrastriatal injection of 
AMPA induces robust neuronal death within 24h 
followed by a neuroinflammatiory response. Here we 
obtained a consistent 70-80% loss of neurons in the 
striatum as demonstrated by NeuN immunostaining 
(Figure 6), but despite this the decrease in 
18F-IAM6067 uptake as quantified by PET was 
inconsistent, with a significant decrease in the globus 
pallidus (Figure 5B) but only a trend to a decrease in 
the caudate-putamen; although the autoradiography 
analysis revealed a more consistent -38% decrease in 
specific binding in both the caudate-putamen and 
globus pallidus. The inconsistency between PET 
imaging, autoradiography and immunohisto-
chemistry could be due to partial volume effect for the 
PET imaging, the lesioned areas (caudate putamen 
and globus pallidus) are amongst the ROIs with the 





lowest level of S1R and are surrounded by other brain 
region in which the 18F-IAM6067 uptake is higher, 
consequently spill over in the lesion might explain the 
lack of amplitude in the decrease of PET signal when 
compared to autoradiography. The presence of focal 
lesion is also a different paradigm than assessed by 
Ishiwata et al. [67] and Ramakrishnan et al. [68] which 
studied the effect of aging on S1R binding. Firstly, 
these two reports investigated the overall effect of 
aging on the brain levels of S1R rather than disease 
associated neurodegeneration. Secondly, it is 
noteworthy that these two publications report 
contradictory results; Ishiwata et al. [67] reported a 
significant increase (×4.57 fold) in Bmax accompanied 
by a significant decrease in affinity (increased Kd, 
×3.75 fold), resulting in an overall slight increase (×1.2 
fold) in S1R binding potential (BPND) whereas 
Ramakrishnan et al. [68] reported a significant 
decrease (approximately 2 fold) in S1R BPND. 
Furthermore, two different strain of rats were used in 
these 2 studies: Fisher-344 [67] and Wistar Hannover 
rats [68], so possible differences between strains 
cannot be ruled out. Moreover, the results of Ishiwata 
et al. [67] demonstrating a modulation of both Bmax 
and Kd suggests a fine functional modulation of S1R 
rather than only a direct relation with neuronal loss. 
Interestingly, our observation of an increase in S1R in 
the substantia nigra (Supplementary Figure 1A & B) 
supports this theory of a fine modulation of S1R in 
response to neuronal stress or loss. So far, the 
meaning of such modulation of S1R in term of 
neuronal functionality remains to be elucidated. 
Second, we used 6-OHDA-lesioned mice, one of the 
most accepted animal models for PD [69]. In this 
model, we were not able to find any difference in 
18F-IAM6067 specific binding between the ipsilateral 
and contralateral hemispheres in the cingulate cortex, 
striatum, thalamus medio-dorsal and VTA/SN, 
despite clear loss of tyrosine hydroxylase positive 
neurons in the striatum (Figure 7), showing that the 
density or expression of S1R was not sensitive to the 
loss of these neurons. This result is in contradiction 
with the results by Mishina et al. [17] who investigated 
S1R density in 6 PD patients vs 6 controls by 
11C-SA4503 PET. They demonstrated a decrease in 
S1R binding potential (BP) but only in the most 
affected anterior putamen (as assessed by 11C-CFT for 
dopamine transporter and 11C-raclopride for D2 
receptor PET imaging) but interestingly did not detect 
differences between controls and PD patients when 
measuring 11C-SA4503 in the anterior putamen 
bilaterally [17]. They suggested that this result 
supported the use of S1R BP as marker of loss of 
presynaptic dopaminergic neurons in PD [17]. One 
must consider that the 6-OHDA model do not 
reproduce all the hallmarks of the human disease [70] 
and that Mishina et al. performed an in vivo PET 
imaging study whereas we used ex vivo 
autoradiography in mice, so differences in techniques 
and human vs animal model may have contributed to 
the discrepancy between the two studies. Finally, the 
studies cited above used 11C-SA4503 while we used 
18F-IAM6067, and differences in binding sites between 
these ligands cannot be ruled out to explain potential 
differences between our results and those reported in 
these studies. 
In order to further investigate whether S1R 
density is a reliable and sensitive biomarker of 
neuronal loss/dysfunction, we also used post-mortem 
brain sections from AD patients. Again, we showed 
no difference in 18F-IAM6067 specific binding in the 
frontal and temporal cortices between control 
subjects, patients with mild to moderate AD-type 
pathology and patients with established AD. Our data 
are in disagreement with previous data from the 
literature looking at AD patients. Indeed, the binding 
potential of 11C-SA4503, used in a 90min PET study, 
was significantly reduced in the frontal, temporal and 
occipital cortex as well as in the cerebellum and the 
thalamus in AD patients vs controls [18]. Furthermore, 
Hedskog et al. [20] found a decrease of S1R expression 
in post-mortem AD cortical tissue by Western blot 
compared to controls. Additionally, an 
autoradiography study revealed a decrease (26%) in 
3H-DTG binding in the hippocampus of AD patients 
vs controls [19]. Conversely, Hedskog et al. [20] also 
showed that S1R was up-regulated in a mouse model 
of AD [20] while σ2 receptor density was decreased in 
a mouse model of AD in cortical regions and the 
striatum of female, but not male, mice [71]. Again, 
differences between animal models and human 
disease could have contributed to the discrepancies 
between studies. However, there is also a discrepancy 
between our autoradiography study and the one by 
Jansen et al. [19], but it must be noted that 3H-DTG has 
a Ki vs non-selective S1R ligand haloperidol and 
opioid receptor ligand pentazocine of only 5 and 
42nM respectively [72] so is not as specific for S1R as 
18F-IAM6067. This poor selectivity might have led to 
the observation of decreases in binding sites 
encompassing S1R as well as other binding sites such 
as opioidergic receptors, which we have 
demonstrated to be very sensitive to neuronal loss in 
stroke [73, 74]. Finally, there are other points to take 
into consideration when comparing our results with 
those previously published. Firstly, our control group 
pools together ‘true’ control cases (i.e. Braak 0) with 
Braak stage ≤2, this may have biased the value in our 
control group, although it is unlikely since these 
patients had no history of neurological disease and no 





pathological evidence of AD or other degenerative 
brain disease. Moreover, we know from 
neuropathological analysis that the brain of patients 
in the moderate and severe AD had far more 
degeneration and advanced neuropathology than 
those in the control group [75]. Secondly, the number 
of cases used in the study by Hedskog et al. [20] was 
lower (3 and 3) than in our study where we used 23 
cases split in 3 groups (n=7-8 per group), which 
would seem more robust. Thirdly, the cases of our 
study had a higher post-mortem delay (38.6 ± 12.9 
hours for all patients) than those used by Hedskog et 
al. [20] (between 10 and 30 hours) or Jansen et al. [19] 
(14 ± 5 and 12 ± 6 hours for AD patients and controls, 
respectively), and while these were the cases with the 
shortest post-mortem delay we could access, this may 
have influenced the quality of the tissue and the levels 
of detectable S1R. Finally, age is the best known risk 
factor for AD [76], so it is important to know how S1R 
expression changes with age. Overall, it was shown 
by PET imaging in rats that S1R could be either 
slightly increased [67] or decreased [68] with age, 
while in AD S1R has been shown to increase in animal 
model [20] but conversely to decrease in human 
studies [18-20]. Therefore, prediction of how S1R 
density might evolve in neurodegenerative disease 
such as AD, and the use of S1R as direct marker of 
neuronal loss, might not be as straight forward as it 
once seemed with age being a significant confounding 
factor. 
While we cannot totally rule out a potential lack 
of sensitivity of 18F-IAM6067 in our experimental 
settings, the absence of decreases in S1R binding in 
the mouse PD model and AD brains, the increase in 
the substantia nigra in the AMPA model in rats 
(Supplementary Figure 1A & B), taken together with 
previous reports [17, 18, 20, 67, 68] suggest that S1R 
expression and/or binding characteristics are altered 
differently in different population of neurons or 
depending on the paradigms. In the absence of similar 
studies in animal models of neurodegeneration and 
human with tracers such as 18F-fluspidine and 
considering that S1R is a chaperone protein and not a 
neurotransmitter receptor, our results suggest that the 
interpretation of changes in S1R PET tracer uptake 
may be more difficult to interpret than initially 
thought as these may not purely reflect a neuronal 
loss or dysfunction but also more complex 
compensatory mechanisms. 
Conclusion 
The present in vivo PET study in rats shows that 
18F-IAM6067 is a suitable specific and selective S1R 
radiotracer in rodent. Considering the relatively slow 
pharmacokinetics in baboon shown by Moussa et al. 
[28], 18F-IAM6067 may not provide any advantage 
over the currently used (S)-18F-fluspidine for imaging 
S1R in human [62, 63]. Our data in the rat AMPA, 
mouse PD models and in human brain tissue did not 
allow us to conclude positively on the potential use of 
S1R as biomarker for neuronal (dys)function in 
neurodegenerative conditions such as AD or PD. 
Reports about changes in S1R density with age and 
disease are conflicting so far, and with the emergence 
of S1R as a potential therapeutic target in 
neurodegenerative diseases and in tumours, further 
elucidation of the expression, function, density and 
role of S1R is of highest interest. Overall the 
previously published data and the present study 
warrant further investigations on the S1R-system in 
health and disease. 
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